C3i benefits from the well-established Hôpital Maisonneuve-Rosemont (HMR) clinical research unit (CRU) infrastructure, under the leadership of Dr Luigina Mollica, which includes:
- Largest group of principal investigators in the field of hemato-oncology in Québec (26).
- Recognized key opinion leaders (KOL) in most tumor sites
- The network of the CML-MPN Quebec Research Group which regroups hematologists from 20 oncology centers of the province of Québec.
- Expertise in registries and real-world evidence studies
- Networking with other Canadian groups, namely
- the National Cancer Institute of Canada (NCIC)
- The Canadian Blood and Marrow Transplant Group (CBMTG).
- Direct links with the GMP manufacturing and the Biomarker and Diagnostic units.
- Expertise in conducting Chimeric Antigen Receptor (CAR) T-cell and immune check-point inhibitors clinical trials
The CRU offers in-house expertise in all phases of clinical trial development and implementation, including Phase I and IV, as well as in regulatory affairs, including submissions to Health Canada, and in-person interactions with Health Canada. The existing team is currently involved in more than 60 active clinical trials in hematology-oncology trials and also participate in cancer immunotherapy trials.
C3i can leverage the CRU services to establish co-development alliances with biotechnology, pharmaceutical and academic partners. Our goal is to accelerate development of new treatment paradigms and proof-of-concepts and as well as confirmatory trials for new medications and new therapeutic indications for existing medications.
The mission of C3i is to provide a comprehensive expertise for cancer-immunotherapy trials and unmatched performance. C3i intends to leverage the CRU to become the leading CRO in Cancer Immunotherapy for Canada and abroad.